Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a Phase III international study to evaluate the effects of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in patients with chronic heart failure HF and impaired kidney function who have recently experienced a heart failure event. The study aims to assess the impact of these treatments on cardiovascular death and heart failure events, including hospitalizations and other HF-related episodes. Participants are randomly assigned to one of three groups one receiving balcinrenonedapagliflozin 15 mg10 mg capsule plus placebo another receiving balcinrenonedapagliflozin 40 mg10 mg capsule plus placebo and a third group receiving dapagliflozin 10 mg tablet plus placebo capsule. All treatments are given once daily orally, alongside standard care for heart failure and kidney impairment. The study is conducted across approximately 700 sites in about 40 countries. During the trial, participants will be monitored over approximately 36 months for cardiovascular death, heart failure hospitalizations, and heart failure events without hospitalization. Assessments include heart failure symptom scores measured at 24 weeks post-randomization. Researchers will also track total occurrences of cardiovascular and heart failure events, as well as overall mortality. This long-term follow-up aims to evaluate treatment effects on these important health outcomes.
Actively Recruiting
Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.
Actively Recruiting
This trial investigates whether tuberculosis preventive treatment TPT given during the window period after exposure can reduce new tuberculosis infections in children and adolescents who live with someone newly diagnosed with pulmonary tuberculosis. The study compares the rate of new infections, measured by IGRA Interferon-Gamma Release Assay conversion at 12 weeks, between those who receive immediate preventive treatment and those who receive standard care where treatment is only given if infection is detected. The goal is to better prevent tuberculosis infection and contribute to global elimination efforts. Participants are assigned to one of two groups. In the intervention group, all children and adolescents receive weekly doses of isoniazid and rifapentine for 12 weeks regardless of their initial IGRA test results. In the control group, only those who test positive on the IGRA test at the start receive this 12-week treatment. Those in the control group who convert to IGRA-positive during the study will also receive treatment following standard care guidelines. During the study, all participants will have IGRA testing at enrollment and again after 12 weeks to detect new infections. Researchers will monitor treatment effects and adverse events related to the 3HP regimen, as well as measure changes in immune response levels. The study lasts 12 weeks with close follow-up to assess the incidence of tuberculosis infection and the safety of the preventive treatment in this young population.